grinboss

Regeneron Pharmaceuticals

REGN

What is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.

At $945.53 (close on November 18) and with the other assumptions at their starting point, Regeneron Pharmaceuticals's sales would need to grow 16.1% a year for ten years; over its last decade, the median was 13.4%. Value it with your own assumptions.

Its accounts, year by year

Year endSalesGrowthMargin
12/20154,104—41.7%
12/20164,86018.4%38.9%
12/20175,87220.8%44.1%
12/20185,146−12.4%57.6%
12/20196,55827.4%40.8%
12/20208,49729.6%47.2%
12/202116,07289.1%59.4%
12/202212,173−24.3%44.9%
12/202313,1177.8%37.6%
12/202414,2028.3%35.0%
12/202514,3431.0%31.9%

Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Regeneron Pharmaceuticals files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.

The model's starting point

  • Sales growth, years 1 to 10: 7.8% a year.
  • Sales growth after year 10: 2.5% a year.
  • Operating margin, before stock pay: 35.0% of sales.
  • Working capital needed to grow: $36.3 per $100 of new sales.
  • Capital spending: 5.3% of sales.
  • Stock pay to employees: 11.2% of sales.
  • Discount rate, the same for every company: 10%.

These are the six assumptions the page starts with; each user moves them as they see fit.

Reference points

They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.

For

  • It has more cash than debt.
  • It makes $35 of operating profit for every $100 it sells, before stock pay; the median is $18.
  • Its sales grew 13.3% a year on average over 10 years, from $4.1 billion to $14.3 billion; the median of grinboss companies is 6.6%.
  • Its share price moves less than the market: a five-year beta of 0.62; the median is 0.94.

Against

  • It ties up $36 in inventory and unpaid customer bills for every $100 of new sales, more than the median ($2).
  • Its stock pay to employees is high: 11.2% of sales, more than the median (1.5%). That is a part of the company that stops belonging to the shareholders.
  • Its margin has fallen over these years, from 42% to 35%.
  • Its margin jumps from one year to the next: 8.4 points on average, and up to 16.8 in a single year; the median is 2.8 points.

Next results: January 28, 2027.

Other companies in its sector (Health Care)

ResMed (RMD) · Revvity (RVTY) · Solventum (SOLV) · Steris (STE) · Stryker Corporation (SYK) · Bio-Techne (TECH) · Thermo Fisher Scientific (TMO) · Universal Health Services (UHS) · All companies

Loading the model…